bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

1

BRIEF REPORT

3

No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins

2
4

produced from plasma collected before the 2020 pandemic

6

Julia Schwaiger,1 Michael Karbiener,1 Claudia Aberham,2 Maria R. Farcet,1 Thomas R. Kreil1

5

7
8
9

1

Global Pathogen Safety, Baxter AG, now part of the Takeda group of companies, 1221 Vienna,
Austria
2

BioLife, Baxter AG, now part of the Takeda group of companies, 1221 Vienna, Austria

10
11
12

Correspondence: Thomas R. Kreil, PhD, Baxter AG, now part of the Takeda group of companies,

14

Phone: +43 1 20100 247 3860. Fax: +43 1 20100 247 5783.

13

Benatzkygasse 2-6, 1221 Vienna, Austria.

15

E-mail: thomas.kreil@takeda.com

17

SUMMARY: IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-

16
18

CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.

20

RUNNING TITLE: No SARS-CoV-2 neutralization by IVIGs

22

WORD COUNT Text: 1,935 words

19

21

WORD COUNT Abstract: 100 words

No SARS-CoV-2 neutralization by IVIGs

1

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

23

Footnotes

25

Potential conflicts of interest

27

Austria. MK, CA, MRF and TRK have Takeda stock interest.

29

Financial support

24
26
28
30

Authors are employees of Baxter AG, now part of the Takeda group of companies, Vienna,

This study was funded by Baxter AG, now part of the Takeda group of companies, Vienna,

31

Austria.

33

Presented in part

32
34

The results have not been presented anywhere else.

36

Correspondence and requests for reprints

38

Baxter AG, now part of the Takeda group of companies,

40

Phone: +43 1 20100 247 3860. Fax: +43 1 20100 247 5783.

35
37

Thomas R. Kreil, PhD

39

Benatzkygasse 2-6, 1221 Vienna, Austria.

41

E-mail: thomas.kreil@takeda.com

No SARS-CoV-2 neutralization by IVIGs

2

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

42

Abstract

44

similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-

46

The question is of particular relevance for people with immune deficiencies, as their health

48

antibodies against the pathogens in their environment. Testing 54 IVIG preparations, produced

50

coronavirus was confirmed, yet no cross-neutralization of the new SARS-CoV-2 was seen.

52

Keywords

54

antibodies; COVID-19; intravenous immunoglobulin; plasma

43

The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans,

45

reactive, potentially even cross-neutralizing antibodies to the new species in humans is unclear.

47

depends on treatment with immunoglobulin preparations that need to contain neutralizing

49

from plasma collected in Europe and the US, highly potent neutralization of a seasonal

51
53

Primary immunodeficiency; SARS-CoV-2; SARS coronavirus 2 antibody titer; neutralizing

No SARS-CoV-2 neutralization by IVIGs

3

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

55

Background

57

and thus contain a wide variety of antibodies the donors have generated against infectious disease

59

bacterial and viral infections.

61

preparations after a certain proportion of plasma donors have contracted the infection, and

63

to result in neutralizing antibody (nAb) levels high enough for the resulting IVIG to afford

65

US, for example, it took several years before the prevalence of WNV nAbs reached

67

IVIG lots produced from plasma donated in the US. Thereafter, a significant proportion of IVIG

56

Intravenous immunoglobulins (IVIG) are produced from thousands of pooled plasma donations,

58

agents. IVIG can therefore protect people with immune deficiencies (PID) against circulating

60

When a new pathogen emerges, antibodies to the new agent only become detectable in IVIG

62

successfully recovered from it. An even higher number of convalescent plasma donors is needed

64

protection against the new infectious agent. After the arrival of West Nile virus (WNV) in the

66

approximately 0.5% in the plasma donor community, at which point they became detectable in

68

lots even reached in vivo protective levels [1].

70

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread around the globe at

72

The virus belongs to the Coronaviridae family of viruses which contains several species of

74

are in circulation as seasonal respiratory viruses that mostly cause self-limiting and mild

76

respiratory syndrome coronavirus (MERS-CoV) causes a prolonged outbreak mainly limited to

69
71

unprecedented speed, infecting millions of people already within the first 6 months of circulation.

73

importance for human health. The human coronaviruses (hCoVs) 229E, NL63, OC43, and HKU1

75

infections but which can also lead to pneumonia and bronchiolitis [2-4], whereas the Middle East

No SARS-CoV-2 neutralization by IVIGs

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

77

the Arabian Peninsula, and the SARS-CoV and SARS-CoV-2 viruses have established global

79

Due to the widespread and long-term circulation of hCoVs, and the pooling of plasma from

81

hCoV nAb levels, as was shown for example for hCoV-NL63 [5]. Whether these hCoV

83

elucidated. To date, antibody binding assays have shown some cross-reactivity between different

85

neutralization assays have shown no or only very low levels of cross-reactive antibodies [6-8].

87

IVIGs, if they were present, might afford some protection to PIDs, and may even represent a

78

transmissions chains – the latter three associated with significant human mortality.

80

thousands of donors for every lot of IVIG, it was shown that IVIGs contain significant levels of

82

antibodies cross-react with or even neutralize the related SARS-CoV-2 has not been fully

84

hCoVs and SARS-CoV-2, yet functional and therefore clinically more relevant virus

86

The question is of significant clinical relevance, as SARS-CoV-2 cross-neutralizing antibodies in

88

treatment option for COVID-19 patients.

90

The current study tested a representative number of IVIG lots for nAbs against SARS-CoV-2 and

92

pandemic virus by antibodies induced by earlier circulating seasonal coronaviruses. In addition,

94

SARS-COV-2 antibodies are presented.

96

Methods

98

A total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-

89
91

the already longer circulating hCoV-229E, to establish clarity about cross-neutralization of the

93

results from the ongoing monitoring of the plasma donor community for the development of

95

97

IVIG preparations

99

2 were analyzed. The IVIG lots were manufactured from plasma either donated by
No SARS-CoV-2 neutralization by IVIGs

5

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

100

plasmapheresis (source, S), or recovered from whole blood donations (recovered, R), in the US

102

(Austria, Germany, Czech Republic (KIOVIG; Baxter AG, Vienna, Austria; N = 24). These 54

104

to volume constraints).

106

Human plasma samples

108

BioLife Austria.

110

in the same calendar week (CW) at Austrian plasma donation centers (BioLife). The pools were

112

(n=80), CW 20 (n=100), CW 24 (n=80), and CW 28 (n=100) of 2020; i.e. during the SARS-CoV-

114

Austrian Federal Ministry for Social Affairs, Health, Care and Consumer Protection

101

(Gammagard Liquid; Baxter Healthcare Corp., Westlake Village, CA; N = 30), or central Europe

103

IVIG lots were tested in two independent experiments for nAbs (one EU lot in single assay, due

105

107

Two pre-pandemic plasma donations were collected in April and May 2019, respectively by

109

Human plasma pool samples were generated by combination of 6 individual donations obtained

111

assembled from donations collected in CW 13 (n=40), CW 14 (n=80), CW 15 (n=80), CW 16

113

2 pandemic. Cumulative incidence of COVID-19 was calculated from data provided by the

115

(www.sozialministerium.at) and Statistics Austria (www.statistik.at).

117

Detection of SARS-CoV-2 neutralizing antibodies

119

undiluted, or pre-diluted with cell culture medium 1:4, 1:5, 1:10 or 1:20 depending on sample

121

were mixed with virus stock at 103.0 tissue culture infectious doses 50% per milliliter

116

118

SARS-CoV-2 nAb titers were determined in IVIG and human plasma samples that were used

120

amount available, and then serially diluted in 2-fold steps. Equal volumes of sample dilutions

122

(TCID50/mL) SARS-CoV-2 (strain “BavPat1/2020”, kindly provided by C. Drosten and V.
No SARS-CoV-2 neutralization by IVIGs

6

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

123

Corman, Charité Berlin, Germany) and incubated for 150min +/-15min, before titration on Vero

125

dilution. The virus-induced cytopathic effect was determined after 5-7 days of incubation. The

127

Spearman-Kärber formula, and the calculated neutralization titer for 50% of the wells reported as

129

for 1:5 prediluted, <1:7.7 for 1:10 prediluted and <1:15.4 for 1:20 prediluted IVIG.

131

input virus infectivity, cell viability, and neutralization testing of an internal reference standard,

124

cells (Cat. no. 84113001, ECACC, Porton Down, Salisbury, UK) in eight-fold replicates per

126

reciprocal sample dilution resulting in 50% virus neutralization (NT50) was determined using the

128

1:X. The detection limits were as follows: <1:0.8 for undiluted, <1:3.1 for 1:4 prediluted, <1:3.9

130

The neutralization assay (µNT) included several validity criteria, i.e. confirmatory titration of

132

all of which had to comply with defined ranges.

134

Detection of hCoV-229E neutralizing antibodies

136

where samples were used undiluted or pre-diluted, then serially diluted in 2-fold steps and mixed

138

titrated on MRC-5 cells (ATCC, Cat. no. CCL-171, Rockville, MD). The virus-induced

133

135

The neutralization assay for hCoV-229E antibodies is essentially identical to the SARS-CoV-2,

137

1:2 with 103.0 TCID50/mL hCoV-229E (ATCC, Cat. no. VR-740, Rockville, MD), incubated and

139

cytopathic effect was determined after 7-9 days of incubation.

141

Graphs and statistical analysis

143

v8.1.1 software (San Diego, CA).

140

142

Graphical illustration and statistical analysis (paired t-tests) were done using GraphPad Prism

144

No SARS-CoV-2 neutralization by IVIGs

7

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

145

Results

147

demonstrated by the analysis of 100 convalescent plasma donations from PCR-confirmed SARS-

149

CoV-2 did not contain SARS-CoV-2 nAbs, as expected, yet neutralized hCoV-229E with NT50

146

The validity and reliability of the SARS-CoV-2 neutralization assay used in the current study was

148

CoV-2 cases [9]. As controls, two plasma samples collected before the emergence of SARS-

150

values of 1:43 and 1:26, respectively.

152

Testing of IVIG

154

of geographic origin of the plasma (EU vs. US) and plasma collection modality (recovered vs.

156

In contrast, hCoV-229E nAb titers between 1:43 and 1:196 (mean=1:98) were measured for the

158

significantly higher levels of nAb to hCoV-229E as compared to IVIG lots produced from source

160

difference was also found between IVIG lots manufactured from source plasma collected in

151

153

SARS-CoV-2 nAb titers were below the limit of detection for all 54 IVIG lots tested, irrespective

155

source) (Figure 1A).

157

54 IVIG lots tested (Figure 1B). IVIG lots produced from recovered plasma contained

159

plasma, independent of the geography of origin. A significant, although quantitatively minor,

161

either the US or the EU.

163

Testing of human plasma

165

community, samples of plasma pools of 6 donations each were tested. The use of pools enabled

162

164

To evaluate the potential development of SARS-CoV-2 antibodies in the plasma donor

166

to test a high amount of plasma donations for SARS-CoV-2 nAbs with the BSL-3 functional

No SARS-CoV-2 neutralization by IVIGs

8

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

167

assay. As the mean SARS-CoV-2 µNT50 of plasma donations is rather high (approx. 1:230 [9])

169

Testing a total of 560 plasma pools of 6 donations each, in total reflective of 3,360 plasma

171

µNT titers below the limit of detection (Table 1). The first pool with detectable nAbs to SARS-

173

CW 28. Up to 7% of the tested pools showed nAbs to SARS-CoV-2, which indicates that up to

175

COVID-19 in Austria of 0.21% (Table 1).

177

Discussion

179

interesting to note that in IVIG lots produced from recovered plasma significantly higher titers to

181

plasma origin. Recovered plasma is usually obtained from elder donors. A trend towards

183

[4] population. Furthermore, higher hCoV-229E specific nAb titers were found in older study

185

rate with hCoV-229E in elder people and consequently the generation of neutralizing hCoV-

187

found in IVIG lots produced from recovered plasma.

168

even the nAbs of only one positive sample within a pool are detectable in this assay.

170

donations, from CW 13 until CW 28, 2020 revealed that most of these pools had SARS-CoV-2

172

CoV-2 was detected in CW 14. Further positive pools were found in CW 15, CW 16, CW24 and

174

1.17% of the plasma donors were positive for SARS-CoV-2 nAbs at a cumulative incidence of

176
178

Our analysis of IVIG lots revealed high nAb titers to hCoV-229E (Figure 1B). It is

180

hCoV-229E were found compared to IVIG lots produced from source plasma, independent of

182

increasing probability of hCoV-229E infections with age was detected in the Scottish [3] and US

184

participants (60-85 years) compared to younger ones (21-40 years) [10]. Thus, a higher infection

186

229E-specific antibodies in the elder plasma donors would explain the higher hCoV-229E titers

188

No SARS-CoV-2 neutralization by IVIGs

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

189
190

Low levels of cross-neutralizing Abs have earlier been demonstrated between specific
pairs of coronaviruses, specifically between SARS-CoV-2 sera and SARS-CoV [6] and SARS-

191

CoV sera and MERS [11].

193

229E nAb titers with a highly specific SARS-CoV-2 µNT did not detect SARS-CoV-2 specific

195

present nAbs against the other seasonal hCoVs, have no cross-neutralizing capacity to SARS-

197

plasma used for production of these IVIG lots, as this plasma was donated well before the start of

192

In clear contrast, testing the same lots of IVIG that were shown to contain high hCoV-

194

nAbs. The finding confirms that the existing hCoV-229E-specfic nAbs, as well as the presumably

196

CoV-2. These results are entirely consistent with the absence of SARS-CoV-2 antibodies in the

198

the SARS-CoV-2 pandemic.

199
200

Surprisingly, Diez et. al. published the detection of cross-reactive [12] as well as cross-

201

neutralizing Abs in 5 of 6 tested IVIG lots (Flebogamma and Gamunex C) [13]. This is in

203

other) with a SARS-CoV-2-specific ELISA (RBD or spike protein) that was shown to correlate

205

as the current study. It is worth noting that the two different methods used by Diez et.al. showed

207

and 3 of [13]).

209

produced from pre-pandemic plasma, currently available IVIGs cannot be expected to afford

202

contrast to an earlier study which tested 21 IVIG lots (9 Gamunex C, 10 Gammagard Liquid, 2

204

well with a neutralization test, and revealed the absence of cross-reactive antibodies [14], as well

206

up to 5.000-fold different neutralization titers for the same IVIG preparation (G1, compare Fig. 2

208
210
211

As two experimentally robust studies have not found SARS-CoV-2 nAbs in IVIG lots

protection from SARS-CoV-2 infection.

No SARS-CoV-2 neutralization by IVIGs

10

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

212

With increasing numbers of human infections, also in the plasma donor community, it is

213

interesting to follow the development of antibodies against SARS-CoV-2 in plasma donations

215

release, also in IVIG lots, a longitudinal study currently in progress. In this context it is

217

similar magnitude. After the emergence of WNV in the US, nAb titers became detectable in

219

In Austria, testing of plasma pool samples indicated that up to 1.17% of plasma donors were

221

infections in the US (~4.3 million per July 30, 2020; www.cdc.gov), and an estimated rate of

223

infected already, i.e. 2.2% of the approx. 330 million population. Based on these facts, the

225

fractionation, is expected within the next few months.

227

production of a hyper-IVIG from the plasma of COVID-19 convalescent donors (CoVIg-19), a

229

(https://www.covig-19plasmaalliance.org).

231

Funding

214

and, after the several months production cycle time between plasma donation and IVIG lot

216

noteworthy that the mean nAb titers induced by WNV [1] and SARS-CoV-2 [9] infection are of

218

IVIGs after approx. 0.5% of the population had gone through and recovered from the infection.

220

positive for SARS-CoV-2 nAbs. Based on the current number of reported SARS-CoV-2

222

>40% asymptomatic infections [15], more than 7.2 million people in the US could have been

224

detection of SARS-CoV-2 nAbs in IVIG lots produced from US plasma, the major source for

226
228
230

232

Another, more immediately available possibility for the treatment of COVID-19 is

developmental work currently under way through a large alliance of plasma stakeholders

No additional financial support was received.

No SARS-CoV-2 neutralization by IVIGs

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

233

Acknowledgments

235

Melanie Graf, Jasmin de Silva, Julius Segui (neutralization assays), Veronika Sulzer, Sabrina

237

are gratefully acknowledged. The team of Plasma Analytics, Takeda, Vienna prepared the human

239

Community) and kindly provided by Christian Drosten and Victor Corman (Charité

234

The contributions of the entire Global Pathogen Safety team, most notably Simone Knotzer,

236

Brandtner (cell culture) as well as Eva Ha and Alexandra Schlapschy-Danzinger (virus culture)

238

plasma pool samples. SARS-CoV-2 was sourced via EVAg (supported by the European

240

Universitätsmedizin, Institute of Virology, Berlin, Germany).

No SARS-CoV-2 neutralization by IVIGs

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

241

References

242

1. Planitzer CB, Modrof J, Yu MY, Kreil TR. West Nile virus infection in plasma of blood and

244

2. Greenberg SB. Update on Human Rhinovirus and Coronavirus Infections. Semin Respir Crit

246

3. Nickbakhsh S, Ho A, Marques DFP, McMenamin J, Gunson RN, Murcia PR. Epidemiology of

243
245
247
248

plasma donors, United States. Emerg Infect Dis 2009; 15:1668-70.

Care Med 2016; 37:555-71.

Seasonal Coronaviruses: Establishing the Context for the Emergence of Coronavirus Disease
2019. J Infect Dis 2020; 222:17-25.

249

4. Killerby ME, Biggs HM, Haynes A, Dahl RM, Mustaquim D, Gerber SI, Watson JT. Human

251

5. Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, van der Hoek L. Inhibition

250

coronavirus circulation in the United States 2014-2017. J Clin Virol 2018; 101:52-6.

252

of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob

254

6. Anderson DE, Tan CW, Chia WN, et al. Lack of cross-neutralization by SARS patient sera

256

7. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody

253
255

Agents Chemother 2006; 50:2000-8.

towards SARS-CoV-2. Emerg Microbes Infect 2020; 9:900-2.

257

mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and

259

[Preprint]. April 17, 2020 [cited 2020 Jul 30]. Available from:

258

association of antibody responses with severity of disease. medRxiv 2020.04.14.20065771

260

https://doi.org/10.1101/2020.04.14.20065771.

261
262
263

8. Okba NMA, Muller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 2020;
26:1478-88.

No SARS-CoV-2 neutralization by IVIGs

13

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

264

9. Jungbauer C, Weseslindtner L, Weidner L, Gänsdorfer S, Farcet MR, Gschaider-Reichhart E,

265

Kreil TR. Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations.

267

https://doi.org/10.1101/2020.06.21.163444.

266

bioRxiv 2020.06.21.163444 [Preprint]. June 21, 2020 [cited 2020 Jul 30]. Available from:

268

10. Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared

269
270
271
272
273
274
275
276
277

with younger adults and binding antibodies are more sensitive than neutralizing antibodies in
identifying coronavirus-associated illnesses. J Med Virol 2020; 92:512-7.
11. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients'
sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent
and neutralizing antibody tests. J Infect 2013; 67:130-40.
12. Diez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains
antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.
Immunotherapy 2020; 12:571-6.
13. Diez JM, Romero C, Vergara-Alert J, et. al. Cross-neutralization activity against SARS-CoV-

278

2 is present in currently available intravenous immunoglobulins. bioRxiv 2020.06.19.160879

280

https://doi.org/10.1101/2020.06.19.160879.

279

[Preprint]. June 19, 2020 [cited 2020 Jul 30]. Available from:

281

14. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2

283

15. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative

282
284

seroconversion in humans. Nat Med 2020; 26(7):1033-1036

Review. Ann Intern Med 2020; M20-3012.

285
286

No SARS-CoV-2 neutralization by IVIGs

14

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.228213; this version posted July 30, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

287

FIGURE LEGEND

289

(n=54) against A. SARS-CoV-2 and B. hCoV-229E. The IVIG lots were manufactured from

291

(recovered, R), in the US or central Europe. Each dot represents the mean of 2 independent

293

shown). The lines represent the median in each group. Paired t-tests were used for determination

288

Figure 1. Coronavirus neutralizing antibody titers in intravenous immunoglobulin (IVIG) lots

290

plasma either donated by plasmapheresis (source, S), or recovered from whole blood donations

292

experiments (except in panel B: from 1 EU-R IVIG lot the titer of a single determination is

294

of significance. LOD: limit of detection;

295

A

B

250

p<0.0001

p=0.0036

200

µNT50 Titer [1:X]

µNT50 Titer [1:X]

200

250

150
100
50
9
6
3
0

LOD

US-R
n=15

US-S
n=15

EU-R
n=9

EU-S
n=15

150
100
50
9
6
3
0

LOD

US-R
n=15

US-S
n=15

EU-R
n=9

EU-S
n=15

296
297

No SARS-CoV-2 neutralization by IVIGs

15

298

299

Table 1. SARS-CoV-2 neutralizing antibodies in tested plasma pools.
Calendar week (2020)

13

14

15

16

20

24

28

Plasma pools ≥LOD [%]

0.0

1.3

1.3

6.3

0.0

5.0

7.0

µNT50 of plasma pool

-

37

5

6, 18, 26,

-

7, 10, 20,

4, 7, 8, 9,

22

12, 18, 24

titers ≥LOD [1:X]

34, 87

Number of plasma pools

40

80

80

80

100

80

100

0.00

0.21

0.21

1.04

0.00

0.83

1.17

0.10

0.14

0.16

0.17

0.18

0.19

0.21

tested
SARS-CoV-2 nAb
positive plasma donors
[%] in Austria
Cumulative COVID-19
incidence [%] in Austriaa
300
301

Abbreviations: LOD, limit of detection; µNT50, neutralization titer for 50% of the wells
a

SARS-CoV-2 PCR-positive individuals per 100,000 population in Austria are described as cumulative COVID-19 incidence in percent.

302
303

No SARS-CoV-2 neutralization by IVIGs

16

